eXoZymes

Historical price data

eXoZymes is a US-based public biotech company (EXOZ) developing an AI-enhanced, cell-free biomanufacturing platform to produce complex small molecules. Its core innovation involves engineering isolated 'exozymes' for predictable, high-yield production outside living cells, addressing key limitations in synthetic biology. Recent milestones include a successful technology transfer and pilot-scale validation with Cayman Chemical in March 2026, de-risking its platform and demonstrating commercial viability. The company's strategy leverages a capital-light, platform-enabled model to pursue multiple high-value programs across metabolic health, cannabinoids, and fragrance ingredients.

AI-enhanced, cell-free biomanufacturing platform that engineers isolated 'exozymes' for the scalable and sustainable production of high-value small molecules.

Competes with cell-based synthetic biology firms (e.g., Ginkgo Bioworks) and enzyme engineering companies (e.g., Codexis). Its key differentiation is the cell-free approach, which aims to avoid scaling bottlenecks, and its integrated AI platform focused on designing enzymes for industrial stability and function.